On May 14, Ge Longhui Life (300642.SZ) announced that due to biotechnology's business development needs, it plans to increase its registered capital from RMB 35 million to RMB 38.5 million. The total amount of capital increase is RMB 20 million. Shanghai Zhang Keling Yifan Venture Capital Center (limited partnership) and the company jointly pledged, and the rest of the shareholders relinquished their priority subscription rights. Among them: Zhang Kelingyi invested RMB 11 million to subscribe to Maxbiotech with an additional registered capital of RMB 1.925 million; the company invested RMB 9 million to subscribe to Maxbiotech with an additional registered capital of RMB 1.575 million. After the capital increase was completed, the total shareholding ratio between the company and Perspective Diagnosis was 59.19%, which will not result in a change in the scope of the company's consolidated statements. MacShiBiotech is still the company's holding subsidiary.
透景生命(300642.SZ)：拟对控股子公司脉示生物增资
Insight Life (300642.SZ): Plans to increase capital in the holding subsidiary Maze Biotech
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.